

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Yestar Healthcare Holdings Company Limited

巨星醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2393)

CHANGE OF EXECUTIVE DIRECTORS

The Board announces that:

1. Mr. Li Bin has tendered his resignation as an executive Director of the Company with effect from 31 December 2021; and
2. Mr. Liang Junxiong has been appointed as an executive Director of the Company with effect from with effect from 31 December 2021.

RESIGNATION OF AN EXECUTIVE DIRECTOR

The board (the “Board”) of directors (the “Directors”) of Yestar Healthcare Holdings Company Limited (the “Company”) hereby announces that Mr. Li Bin (“Mr. Li”) has tendered his resignation as an executive Director of the Company with effect from 31 December 2021 due to his health problem.

Mr. Li has confirmed to the Board that he has no disagreement with the Board and there is nothing relating to his resignation that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange of Hong Kong Limited (the “Stock Exchange”).

The Board would like to take this opportunity to express its gratitude to Mr. Li as an executive Director for his contributions to the Company during his terms of service.

APPOINTMENT OF AN EXECUTIVE DIRECTOR

The Board further announces that Mr. Liang Junxiong (“Mr. Liang”) has been appointed as an executive Director of the Company with effect from 31 December 2021. The biographical details of Mr. Liang is set out below:

Mr. Liang Junxiong, aged 49, joined the Group in March 2011 and is the financial controller of various subsidiaries of the Company. He is primarily responsible for overseeing the financial and accounting matters of Yestar (Guangxi) Technology Co., Ltd., a wholly-owned subsidiary of the Company.

Mr. Liang has over 25 years of experience in accounting, auditing and financial management. Prior to joining our Group, Mr. Liang worked for 廣西博科藥業公司 as a cost accountant from March 2004 to February 2008 and for 高立工貿公司 as the financial manager from March 2008 to February 2011.

Mr. Liang graduated from Guangxi University in 1998, majoring in financial management. He passed the examination for Certified Public Accountant (CPA) qualification in China in 2009 and is certified as a CPA in China. He is currently a non-practicing member of the Chinese Institute of Certified Public Accountants. He also passed the examination for Certified Management Accountant (CMA) qualification in the United States in 2018.

Mr. Liang has entered into a service agreement with the Company for an initial term of three years with effect from 31 December 2021, subject to normal retirement and re-election by shareholders of the Company pursuant to the articles and association of the Company. Mr. Liang is entitled to an annual salary of approximately RMB404,882, which was determined with reference to his duties and responsibilities, the Company’s remuneration policy, the prevailing market conditions and recommendations of the remuneration committee of the Board. Mr. Liang’s remuneration will be subject to annual review by the remuneration committee of the Board and the Board from time to time with reference to his responsibility and performance.

Mr. Liang shall hold office until the next general meeting of the Company and will be eligible for and subject to re-election at such meeting in accordance with the articles of association of the Company.

Save as disclosed above, Mr. Liang does not hold any other positions in the Company or its subsidiaries nor any directorship in other listed public company in the last three years.

Mr. Liang does not have any relationship with any Directors, senior management, substantial or controlling Shareholders (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the “Listing Rules”)) of the Company.

Further, Mr. Liang does not have, and is not deemed to have, any interests or short positions in any shares, underlying shares or debentures (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)) (the “SFO”) of the Company as at the date of this announcement.

Save as disclosed above, to the best of the knowledge, information and belief of the Directors after having made all reasonable enquiries, there was no matter relating to the appointment of Mr. Liang as an executive Director that needs to be brought to the attention of the Shareholders and there is no other information which is required to be disclosed pursuant to any requirements of Rules 13.51(2)(h) to (v) of the Listing Rules.

The Board would also like to express its warmest welcome to Mr. Liang on his appointment.

By Order of the Board
Yestar Healthcare Holdings Company Limited
Hartono James
Chairman, CEO and Executive Director

31 December 2021

As at the date of this announcement, the executive Directors are Mr. Hartono James, Ms. Wang Hong, Ms. Liao Changxiang and Mr. Liang Junxiong; the independent non-executive Directors are Dr. Hu Yiming, Mr. Zeng Jinsong and Mr. Sutikno Liky.